Further trials are warranted to elucidate the role of anti-PD-1/PD-L1 agents in the treatment paradigm for patients with EGFR-mutant NSCLC and determine whether baseline tumour PD-L1 expression is predictive of improved durability of response. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.